Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (201-210 of 339) with videos related to

Pageof 34
Sort By:
British Journal of Haematology|May 16, 2020
Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry GroupUrsula Rochau, Igor Stojkov, Annette Conrads-Frank, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaPierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
Annals of Hematology|June 7, 2020
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemiaHeiko Becker, Dietmar Pfeifer, Gabriele Ihorst, et al.
Oncotarget|November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapyThomas Prebet, Thomas Cluzeau, Sophie Park, et al.
Leukemia Research|February 24, 2005
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaMignon L Loh, Simone Martinelli, Viviana Cordeddu, et al.
Cancer Medicine|September 18, 2015
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependenceEsther N Oliva, Michael Lauseker, Maria Antonietta Aloe Spiriti, et al.
Hemasphere|September 24, 2024
Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDSPaolo Mazzeo, Christina Ganster, John Wiedenhöft, et al.
Blood|February 2, 2013
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemiaEsperanza Such, Ulrich Germing, Luca Malcovati, et al.
Plos One|October 12, 2013
Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized dataRonald Brand, Hein Putter, Anja van Biezen, et al.
Transplantation and Cellular Therapy|October 11, 2020
Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic LeukemiaNico Gagelmann, Rashit Bogdanov, Friedrich Stölzel, et al.
Pageof 34

Showing results (201-210 of 339) with videos related to

Sort By:
Pageof 34
British Journal of Haematology|May 16, 2020
Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry GroupUrsula Rochau, Igor Stojkov, Annette Conrads-Frank, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaPierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
Annals of Hematology|June 7, 2020
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemiaHeiko Becker, Dietmar Pfeifer, Gabriele Ihorst, et al.
Oncotarget|November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapyThomas Prebet, Thomas Cluzeau, Sophie Park, et al.
Leukemia Research|February 24, 2005
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaMignon L Loh, Simone Martinelli, Viviana Cordeddu, et al.
Cancer Medicine|September 18, 2015
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependenceEsther N Oliva, Michael Lauseker, Maria Antonietta Aloe Spiriti, et al.
Hemasphere|September 24, 2024
Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDSPaolo Mazzeo, Christina Ganster, John Wiedenhöft, et al.
Blood|February 2, 2013
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemiaEsperanza Such, Ulrich Germing, Luca Malcovati, et al.
Plos One|October 12, 2013
Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized dataRonald Brand, Hein Putter, Anja van Biezen, et al.
Transplantation and Cellular Therapy|October 11, 2020
Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic LeukemiaNico Gagelmann, Rashit Bogdanov, Friedrich Stölzel, et al.
Pageof 34